Jeffrey Fajardo, MD
Endocrinology, Diabetes & Metabolism · Topeka, KSNPI 1861499881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,711 and has fallen 97.5% since, to $42 in 2024.
Across 177 payments — averaging $12.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$511
- Lilly USA, LLC$309
- Novo Nordisk$306
- AbbVie$201
- AstraZeneca$192
- Amgen$120
- plus $584 from 15 others
What the payments were for
- Food & beverage$2,18298%
- Education$412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 34 | $511 |
| Lilly USA, LLC | 32 | $309 |
| Novo Nordisk | 25 | $306 |
| AbbVie | 15 | $201 |
| AstraZeneca(2 entities) | 9 | $192 |
| Amgen | 12 | $120 |
| Boehringer Ingelheim | 18 | $117 |
| Corcept Therapeutics | 5 | $66 |
| Ipsen Biopharmaceuticals, Inc | 4 | $63 |
| Antares Pharma, Inc. | 3 | $46 |
| Regeneron Healthcare Solutions, Inc. | 3 | $44 |
| Pfizer | 3 | $44 |
| Medtronic | 3 | $41 |
| Dexcom, Inc. | 2 | $38 |
| Insulet Corporation | 2 | $34 |
| Sandoz | 2 | $27 |
| Radius Health, Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$2,223 in reported general payments places this provider in the 55th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 137 | $177,283 |
| JardianceEmpagliflozin | 160 | $165,195 |
| JanuviaSitagliptin Phosphate | 49 | $72,466 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $38,956 |
| MounjaroTirzepatide | 33 | $34,673 |
| TradjentaLinagliptin | 28 | $24,409 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $23,911 |
| GenotropinSomatropin | 17 | $23,660 |
| FarxigaDapagliflozin Propanediol | 20 | $21,663 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $11,937 |
| Novolog FlexpenInsulin Aspart | 54 | $11,806 |
| TrulicityDulaglutide | 14 | $11,688 |
| SynthroidLevothyroxine Sodium | 190 | $11,345 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $7,813 |
| OmnitropeSomatropin | 12 | $7,526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $117 | $197,417201 claims |
| Novo NordiskOzempic | $306 | $177,283137 claims |
| Lilly USA, LLCMounjaro, Trulicity | $309 | $46,36147 claims |
| PfizerGenotropin | $44 | $23,66017 claims |
| AstraZenecaFarxiga | $192 | $21,66320 claims |
| AbbVieSynthroid | $201 | $11,345190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Topeka
- Susan BrianTopeka$9K
- Alan WynneTopeka$8K
- Christine UyTopeka$7K
- Bahaa Abu BakrTopeka$3K
- Su Ah BaeTopeka$2K
- Francisco CorreaTopeka$2K
- Noor AddasiTopeka$741
- Dana AwadTopeka$340
- Vidita DivanTopeka$276
- Kaitlin DitchTopeka$249
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.